Search Results - "Beaumont, K C"

Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man by BEAUMONT, K. C., CUSSANS, N. J., NICHOLS, D. J., SMITH, D. A.

“…1. Followingintravenousadministrationto animals at 2 5 mg kg, darifenacinexhibited terminal plasma half-lifes < 2 h due to high plasma clearance (with respect…”
Get full text

Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man by Abel, S., Beaumont, K. C., Crespi, C. L., Eva, M. D., Fox, L., Hyland, R., Jones, B. C., Muirhead, G. J., Smith, D. A., Venn, R. F., Walker, D. K.

“…1. UK-343,664 is a potent and specific PDE5 inhibitor. Following single oral doses to human volunteers, it exhibited non-proportional pharmacokinetics over the…”
Get full text

Pharmacokinetics and metabolism of zamifenacin in mouse, rat, dog and man by Beaumont, K C, Causey, A G, Coates, P E, Smith, D A

“…1. Zamifenacin was rapidly metabolized in vitro by liver microsomes from rat, dog, and man. 2. Zamifenacin exhibited extensive plasma protein binding with…”
Get more information

Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog by Walker, D. K., Beaumont, K. C., Comby, P., Evans, K. M., Gedge, J. I., Halliday, R. C., Roffey, S. J., Wright, P. A.

“…1. UK-343,664 is a novel potent and selective PDE5 inhibitor. Plasma clearances in the male and female rat were high (120 and 54 ml min-1 kg-1), giving rise to…”
Get full text

Pharmacokinetics of a series of bis(methanesulphonamido-arylalkyl)amines in the beagle dog by Walker, D K, Beaumont, K C, Stopher, D A, Smith, D A

“…1. The pharmacokinetics of three closely related analogues of dofetilide have been investigated in the beagle dog. These have been compared with those of…”
Get more information

Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man by Abel, S, Beaumont, K C, Crespi, C L, Eve, M D, Fox, L, Hyland, R, Jones, B C, Muirhead, G J, Smith, D A, Venn, R F, Walker, D K

“…1. UK-343,664 is a potent and specific PDE5 inhibitor. Following single oral doses to human volunteers, it exhibited non-proportional pharmacokinetics over the…”
Get full text

Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog: The Drug Metabolism Discussion Group in 2001 by WALKER, D. K, BEAUMONT, K. C, COMBY, P, EVANS, K. M, GEDGE, J. I, HALLIDAY, R. C, ROFFEY, S. J, WRIGHT, P. A

Get full text

Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man: The Drug Metabolism Discussion Group in 2001 by ABEL, S, BEAUMONT, K. C, WALKER, D. K, CRESPI, C. L, EVE, M. D, FOX, L, HYLAND, R, JONES, B. C, MUIRHEAD, G. J, SMITH, D. A, VENN, R. F

Get full text